E7

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

Retrieved on: 
수요일, 3월 27, 2024
MSD, Research, Conference call, Conference, Head, AstraZeneca, E7, Patient, Merck & Co., Tumor microenvironment, Merck, News, R&I, Cancer, Virus, MD, E6, Lung cancer, AACR, NEC, European Journal, HPV16, Euronext Paris, De novo, Immune system, ASCO, Safety, Poster, Potyvirus, Pharmaceutical industry

Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.

Key Points: 
  • Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
  • “During 2023 Transgene continued to make significant progress, delivering compelling data that confirm the value of our approach to treating cancer using our novel immunotherapies” commented Dr. Alessandro Riva, MD, Chairman and CEO of Transgene.
  • As announced on May 5, 2023, AstraZeneca terminated its oncolytic virus research and development collaboration with Transgene following a strategic review of its pipeline.
  • In 2024, Transgene expects to communicate progress and significant results and readout on all of its clinical stage assets.

Cabot Corporation Launches New PROPEL® E8 Engineered Reinforcing Carbon Black for Tire Tread Applications

Retrieved on: 
월요일, 3월 18, 2024
Environment, Alternative Vehicles, Fuels, EV, Electric Vehicles, Aftermarket, Automotive, Chemicals, Plastics, Automotive Manufacturing, Manufacturing, Sustainability, EVS, E7, Corporation, ASTM, PROPEL, E6, ICE, Carbon, Torque, Cabot Corporation, Tire manufacturing

Cabot Corporation (NYSE: CBT) today announced the global launch of its new PROPEL® E8 engineered reinforcing carbon black designed to provide superior tread durability at low rolling resistance for high-performance tire tread applications.

Key Points: 
  • Cabot Corporation (NYSE: CBT) today announced the global launch of its new PROPEL® E8 engineered reinforcing carbon black designed to provide superior tread durability at low rolling resistance for high-performance tire tread applications.
  • The PROPEL E8 grade complements Cabot’s existing solutions within the PROPEL E series, which are also suitable for use in high-performance tires.
  • The PROPEL E8 solution enables better rolling resistance when compared to ASTM N200 and N100 carbon black grades.
  • For more information about Cabot’s comprehensive suite of products for EV tires and high-performance tire tread applications, visit cabotcorp.com/tire .

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Retrieved on: 
목요일, 1월 25, 2024
Tumor microenvironment, Death, Patient, Therapy, Neoplasm, AMP, Cancer, E7, Peptide, Immunotherapy, Risk, Recurrence, Lymph, Cancer Immunology Research, Doctor of Philosophy, NY-ESO-1, Research, Vaccine

These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies (“TCR-T cells”) enhancing anti-tumor function and eradicating solid tumors.

Key Points: 
  • These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies (“TCR-T cells”) enhancing anti-tumor function and eradicating solid tumors.
  • “Optimization of TCR-T cell therapy could potentially have wide-ranging therapeutic benefits in many previously intractable solid tumors,” said Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics.
  • “In this study, we’ve demonstrated that boosting TCR-T cell therapy directly in the lymph nodes with AMP immunotherapy resulted in durable anti-tumor T cell responses and tumor eradication.
  • AMP immunotherapy led to enhanced lymph node delivery and correlated with pro-inflammatory lymph node transcriptional reprogramming and increased antigen-presenting cell maturation, resulting in TCR-T cell expansion and functional enhancement.

Down Syndrome Clinical Trials 2023: Comprehensive Global Analysis Report, Highlighting Regional Trends, Phases, and Sponsor Types - ResearchAndMarkets.com

Retrieved on: 
금요일, 12월 22, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Clinical trial, Trial, News, G7, E7, Down syndrome, Pharma, Clinical, Pharmaceutical industry

The clinical trial report, provides an overview of Down Syndrome Clinical trials scenario.

Key Points: 
  • The clinical trial report, provides an overview of Down Syndrome Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Down Syndrome.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Retrieved on: 
일요일, 10월 22, 2023
Neoplasm, The Mark of Gideon, E6, ESMO, Progression-free survival, DCR, Pembrolizumab, LCMV, Congress, Arenavirus, E7, CPI, Memorial Sloan Kettering Cancer Center, HPV16, COVID, Immune system, Oncology, ORR, ELISPOT, RECIST, DCO, Safety, Patient, Pharmaceutical industry, Vaccine

All evaluable patients were alive at the data cutoff (DCO), and the median follow-up time at DCO was 8.3 months.

Key Points: 
  • All evaluable patients were alive at the data cutoff (DCO), and the median follow-up time at DCO was 8.3 months.
  • Importantly, results showed significant activation of antigen-specific CD8+ T cells, the body’s primary driver of tumor killing activity.
  • Out of 17 patients with available peripheral blood mononuclear cells (PMBC) samples, all patients showed an increase of tumor antigen-specific circulating HPV16+ CD8+ T cells.
  • These data represent a doubling of the 19 percent ORR reported for pembrolizumab alone1 and are consistent with previously reported HB-200 data.

Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024

Retrieved on: 
수요일, 9월 20, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, MSD, Head, MBA, Phase II, Doctor of Philosophy, Journal, Patient, Potyvirus, Epitope, Merck, NEC, La Jolla Institute for Immunology, FRCP, University, HPV16, Research, Lung cancer, Merck & Co., De novo, University of Liverpool, CD8, Cervical cancer, CTL, Biology, Immunology, Phase, Safety, AACR, E6, Immune system, University of Lausanne, European Journal, KOL, European Journal of Cancer Prevention, Bank statement, AstraZeneca, E7, ASCO, Euronext Paris, Statutory auditor, Combined, Immunotherapy, Tumor microenvironment, Pharmaceutical industry, Vaccine, Computer data storage, Cancer, MD, TG4050, Transgene

We are planning together with our partner NEC to start a randomized Phase II trial in 2024.

Key Points: 
  • We are planning together with our partner NEC to start a randomized Phase II trial in 2024.
  • Transgene and NEC intend to start a randomized Phase II trial in the adjuvant setting of head and neck cancer in 2024.
  • Transgene is assessing all options to ensure data read out in 2024 from the trial as previously communicated.
  • The Board of Directors of Transgene met on September 20, 2023, and approved the financial statements for the six-month period ended June 30, 2023.

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 8월 10, 2023
Novartis Institute for Tropical Diseases, Gene, HLA, ALL, MAGE-A1, Papillomaviridae, Clinical trial, HPV16, Cancer, Biomedical Research, PRAME, TCR, MDS, E7, ASCO, Acute myeloid leukemia, Trial of the century, AML, American Society of Clinical Oncology, Patient, Syndrome, Annual general meeting, Cell, Acute leukemia, IND Culver Line, Toxic shock syndrome toxin-1, Poster, Research, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Safety, Society, Food, Pharmaceutical industry, Life insurance, Video game, Amgen

WALTHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor-engineered T cell therapies (TCR-Ts) for the treatment of patients with cancer, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

Key Points: 
  • Revenue for the second quarter ended June 30, 2023, was $3.1 million, compared to $4.1 million for the second quarter ended June 30, 2022 (2022 Quarter).
  • Research and development expenses for the second quarter ended June 30, 2023, were $21.2 million, compared to $14.5 million for the 2022 Quarter.
  • General and administrative expenses for the second quarter ended June 30, 2023, were $6.5 million, compared to $4.8 million for the 2022 Quarter.
  • For the second quarter ended June 30, 2023, TScan Therapeutics reported a net loss of $24.0 million, compared to a net loss of $15.1 million for the 2022 Quarter.

Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme - ResearchAndMarkets.com

Retrieved on: 
목요일, 7월 20, 2023
Health, Pharmaceutical, CIN, Artesunate, Society, Therapy, Clinical trial, NDA, Woman, Society of Gynecologic Oncology, Cervical intraepithelial neoplasia, Research, Candidiasis, E7, Discovery, E6, Gynaecology, HPV, Growth, Intraepithelial neoplasia, III, Inovio Pharmaceuticals, Human papillomavirus infection, News, Birth control, Pharmaceutical industry, Gynecologic Oncology (journal), Cervical, Phase

The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.
  • This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs.
  • The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e.

Inaugural SuperBridge Summit Dubai to Convene Future Minded Leaders From World’s Fastest-Growing Economies

Retrieved on: 
수요일, 6월 21, 2023
Professional Services, Business, Thought Leadership, Finance, Human, Culture, Policy, Multimedia, Gap, E7, Future, Organization, Museum of the Future, Dubai World Trade Centre, AED, Museum, Tourism, Environment, Summit, Drug, Renewable energy

KAOUN International, a subsidiary of Dubai World Trade Centre (DWTC), and the SuperBridge Council have today announced the inaugural edition of the SuperBridge Summit Dubai, which will debut at the Museum of the Future in Dubai on 16-17 October 2023.

Key Points: 
  • KAOUN International, a subsidiary of Dubai World Trade Centre (DWTC), and the SuperBridge Council have today announced the inaugural edition of the SuperBridge Summit Dubai, which will debut at the Museum of the Future in Dubai on 16-17 October 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230621053201/en/
    HE Helal Saeed Al Marri, Director General of Dubai's Department of Economy and Tourism, and DWTC (Photo: AETOSWire)
    The summit is an exciting new platform that will convene over 500 business, policy and cultural leaders from 20 countries, representing the world’s fastest-growing economies.
  • A multi-disciplinary platform that ignites, connects and unites future-minded leaders from the world’s fastest-growing economies across industries and culture,” said Shane Tedjarati, Co-founder, SuperBridge Council and Chairman of VS Partners.
  • SuperBridge provides access to global capital that seeks future-proofing investment opportunities,” she said.

Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Retrieved on: 
월요일, 6월 5, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Antigen, NCT, RECIST, HPV16, Cancer, Trial of the century, E7, ASCO, Euronext Paris, American Society of Clinical Oncology, MD, Patient, E6, Annual general meeting, HPV, Poster, Society, Avelumab, Vaccine, Pharmaceutical industry, Transgene

These data confirm the ability of this novel investigational therapeutic cancer vaccine to induce immune responses against HPV16 antigens, that are associated with anti-tumor response.

Key Points: 
  • These data confirm the ability of this novel investigational therapeutic cancer vaccine to induce immune responses against HPV16 antigens, that are associated with anti-tumor response.
  • These results have been presented in a poster at the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • These data clearly demonstrate that Transgene’s TG4001 could induce a specific immune response against the antigens vectorized within this vaccine.
  • These data further confirm that our therapeutic vaccine TG4001 can induce clinically meaningful immune responses, that are associated with antitumor response.